15:45:59 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-11-22 Kvartalsrapport 2024-Q3
2024-08-30 Kvartalsrapport 2024-Q2
2024-05-24 Kvartalsrapport 2024-Q1
2024-05-20 Ordinarie utdelning CMH 0.00 SEK
2024-05-17 Årsstämma 2024
2024-03-22 Bokslutskommuniké 2023
2024-01-26 Extra Bolagsstämma 2024
2023-11-01 Kvartalsrapport 2023-Q3
2023-08-31 Kvartalsrapport 2023-Q2
2023-05-25 Kvartalsrapport 2023-Q1
2023-04-14 Ordinarie utdelning CMH 0.00 SEK
2023-02-28 Bokslutskommuniké 2022
2022-12-13 Extra Bolagsstämma 2022
2022-11-18 Kvartalsrapport 2022-Q3
2022-08-30 Kvartalsrapport 2022-Q2
2022-05-27 Kvartalsrapport 2022-Q1
2022-04-26 Ordinarie utdelning CMH 0.00 SEK
2022-04-25 Årsstämma 2022
2022-02-25 Bokslutskommuniké 2021
2021-10-25 Kvartalsrapport 2021-Q3
2021-10-05 Extra Bolagsstämma 2021
2021-08-30 Kvartalsrapport 2021-Q2
2021-05-27 Kvartalsrapport 2021-Q1
2021-04-16 Ordinarie utdelning CMH 0.00 SEK
2021-04-15 Årsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2020-11-20 Kvartalsrapport 2020-Q3
2020-08-18 Extra Bolagsstämma 2020
2020-08-07 Kvartalsrapport 2020-Q2
2020-04-29 Kvartalsrapport 2020-Q1
2020-04-24 Ordinarie utdelning CMH 0.00 SEK
2020-04-23 Årsstämma 2020
2020-02-28 Bokslutskommuniké 2019
2019-11-11 Kvartalsrapport 2019-Q3
2019-08-30 Kvartalsrapport 2019-Q2
2019-05-24 Kvartalsrapport 2019-Q1
2019-05-10 Ordinarie utdelning CMH 0.00 SEK
2019-05-09 Årsstämma 2019
2019-02-28 Bokslutskommuniké 2018
2018-11-16 Kvartalsrapport 2018-Q3
2018-08-31 Kvartalsrapport 2018-Q2
2018-05-25 Kvartalsrapport 2018-Q1
2018-04-27 Ordinarie utdelning CMH 0.00 SEK
2018-04-26 Årsstämma 2018
2018-02-28 Bokslutskommuniké 2017
2017-10-31 Kvartalsrapport 2017-Q3
2017-08-31 Kvartalsrapport 2017-Q2
2017-04-28 Kvartalsrapport 2017-Q1
2017-04-20 Ordinarie utdelning CMH 0.00 SEK
2017-04-19 Årsstämma 2017
2017-02-10 Bokslutskommuniké 2016

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Chordate Medical Holding är ett medicintekniskt bolag som har utvecklat, patenterat och CE-märkt en nervmodulerande behandlingsteknik för kronisk migrän och kronisk nästäppa (rinit), Kinetic Oscillation Stimulation (K.O.S). Bolaget säljer sina produkter till behandlande kliniker på utvalda europeiska marknader, Israel samt Saudiarabien, med målsättningen att öka närvaron på den globala marknaden.
2022-12-14 11:16:00

Chordate Medical ("Chordate", the "Company") has entered into an agreement with one of Saudi Arabia's leading medical device companies, Janin Medical Company ("Janin"), under which Janin will become the exclusive distributor in the Kingdoms of Saudi Arabia and Bahrain for both the migraine and rhinitis indications as of the turn of the year 2022/2023.

The venture in Saudi Arabia and the rest of the Gulf region is led by Chordate's Regional General Manager Alain Durante. The focus for some time has been to establish the right market channel to successfully introduce the company's K.O.S product for the treatment of migraine and rhinitis, which has now resulted in an exclusive distribution agreement with Janin Medical Company in Riyadh.

Janin is a privately held company established in 1996 and based in Riyadh with a local office in Jeddah. The company has a turnover of approximately SEK 25 million and a historically good profitability. The company is a focused importer and distributor of advanced medical devices in neurology, pulmonary medicine, cardiology, speech therapy/audiology and urology. Janin also has the status to bid for public tenders.

“We see Janin's sales targeting neurologists as a good match, they have an established product portfolio and access to all major hospitals and government agencies in the country. With active support from our own representative in Saudi Arabia, this long-term cooperation will allow us to move the positions forward for our important migraine product as well,” says Anders Weilandt, CEO of Chordate.

More information about Janin Medical Company

https://janinmedical.com/index.html